Tango Therapeutics Inc TNGX.OQ TNGX.O is expected to show a rise in quarterly revenue when it reports results on May 12 for the period ending March 31 2025
The Boston Massachusetts-based company is expected to report a 3.4% increase in revenue to $6.694 million from $6.47 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Tango Therapeutics Inc is for a loss of 35 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tango Therapeutics Inc is $10.00, above its last closing price of $1.10.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.33 | -0.34 | -0.35 | Missed | -3.3 |
Sep. 30 2024 | -0.35 | -0.37 | -0.27 | Beat | 26.5 |
Jun. 30 2024 | -0.35 | -0.34 | -0.24 | Beat | 30.4 |
Mar. 31 2024 | -0.31 | -0.31 | -0.35 | Missed | -11.9 |
Dec. 31 2023 | -0.30 | -0.28 | -0.32 | Missed | -15.2 |
Sep. 30 2023 | -0.34 | -0.34 | -0.23 | Beat | 33.3 |
Jun. 30 2023 | -0.31 | -0.34 | -0.23 | Beat | 31.5 |
Mar. 31 2023 | -0.35 | -0.35 | -0.32 | Beat | 8.9 |
This summary was machine generated May 9 at 16:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)